This disclosure relates to a method of treating a proteinopathy in a subject, the method comprising administering to the subject an effective amount of a quinuclidine compound. The disclosure also relates to a method of reducing, reversing or preventing the accumulation of protein aggregates in tissue of a subject diagnosed as having a proteinopathy, or being at risk of developing a proteinopathy, the method comprising administering to the subject an effective amount of a quinuclidine compound. Also disclosed is a pharmaceutical composition comprising a quinuclidine compound for use in said methods. The proteinopathy may be a synucleinopathy or a tauopathy, such as Parkinson’s disease, Alzheimer’s disease or dementia with Lewy bodies.本揭示文係關於治療一對象中蛋白質病變之方法，該方法包括投予該對象一有效量之啶(quinuclidine)化合物。本揭示文亦關於降低、反轉或防止蛋白質聚集物堆積在經診斷患有蛋白質病變或處於發生蛋白病變風險之對象組織的方法，該方法包括投予該對象一有效量之啶化合物。亦揭示包括一啶化合物之醫藥組成物供用於該方法。蛋白質病變可為共核蛋白病變(synucleinopathy)或tau蛋白病變(tauopathy)，例如帕金森氏症、阿茲海默症或路易氏體失智症。
